I for one do not understand the market's current obsession with Daybue numbers when NEU's value is going to be almost entirely tied to progression of 2591 in the not too distant future. Extremely shortsighted in my view but an opportunity to keep adding to one's holding if you believe like I do that 2591 will be a resounding clinical and commercial success.
With respect to the PRV it is interesting to note that if NEU do receive a voucher for PMS and can sell it for US $150 million and if the estimate for phase 3 costs is accurate then the PRV will have paid for probably the entire commercialisation of 2591 for PMS (pre marketing and sales costs). This is in contrast to Acadia's costs of running the trofinetide phase 3 which allegedly pushed US $250-300 million due in large part to the high cost of manufacturing trofinetide.
So a PRV for 2591 may end up comparatively very very valuable.
NEU Price at posting:
$13.81 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)